NASDAQ · EPRX
Eupraxia Pharmaceuticals Inc.
$7.25-$0.13 (-1.76%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.21% below the high.
Loading market information…
NASDAQ · PRLD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Prelude Therapeutics Incorporated’s quoted price sits in the upper half of its reported 52-week range, 39.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Prelude Therapeutics Incorporated’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of $0.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Prelude Therapeutics Incorporated’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | -$0.42+10.64% vs estimate | $0.00 |
|---|
| Q4 2024 | Mar 10, 2025 | -$0.38+20.83% vs estimate | $4.00M |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.43+8.51% vs estimate | $3.00M |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.25-$0.13 (-1.76%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.21% below the high.
$7.44+$0.32 (+4.49%)
Avalo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.34% below the high.
$6.09+$0.10 (+1.67%)
Orchestra BioMed Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.31% below the high.
$11.15-$0.40 (-3.46%)
Enanta Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.99% below the high.
$4.02+$0.03 (+0.75%)
Immuneering Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.59% below the high.
$3.73+$0.02 (+0.54%)
Inventiva S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.83% below the high.
$2.09-$0.04 (-1.88%)
Foghorn Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.54% below the high.
$1.89-$0.09 (-4.55%)
Pyxis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.95% below the high.
